Epson vs Sanofi

Epson to Showcase Connected Restaurant Technology Ecosystem Designed for Accuracy and Efficiency at FS/TEC 2026

Epson announced plans to demonstrate its point-of-sale (POS), kitchen display systems, and other connected restaurant technology at FS/TEC 2026, aiming to improve accuracy and efficiency in restaurant operations.

Epson to Showcase Connected Restaurant Technology Ecosystem Designed for Accuracy and Efficiency at FS/TEC 2026

Epson announced plans to demonstrate its point-of-sale (POS), kitchen display systems, and other connected restaurant technology at FS/TEC 2026, aiming to improve accuracy and efficiency in restaurant operations.

Epson Recognized with Two Retail Industry Awards at RSPA RetailNOW 2026

Epson, a market leader of retail solutions, today announced it was awarded two prestigious awards from the Retail Solutions Providers Association (RSPA) – a bronze ‘Vendor Award of Excellence’ and a Retail IT...

6-K Financial Filing Analysis for Sanofi (2026-09-17)

Am 17. September 2026 reichte Sanofi ein Form 6-K bei der U.S. Securities and Exchange Commission ein, das eine Pressemitteilung vom 14. September 2026 beinhaltet. Die Einreichung kündigt eine neue strategische Partnerschaft zwischen Sanofi und Cheplapharm im Bereich etablierter Medikamente (Mature Medicines) an. Diese Partnerschaft unterstreicht Sanofis kontinuierliche Strategie zur Portfolio-Optimierung, um etablierte pharmazeutische Produkte effizienter zu verwalten oder zu monetarisieren und Ressourcen auf innovative Pipeline-Therapien und Kernwachstumstreiber zu fokussieren.

• Sanofi hat eine strategische Partnerschaft mit Cheplapharm für sein Portfolio an etablierten Medikamenten (Mature Medicines) geschlossen, die am 14. September 2026 per Pressemitteilung bekannt gegeben wurde.
• Die Form 6-K-Meldung wurde am 17. September 2026 offiziell von Alexandra Roger, Head of Legal Corporate & Finance, unterzeichnet und eingereicht.

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

• The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
• Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
• Sanofi is developing a 'lab-in-a-loop' using AI agents to compress discovery work from years to weeks.